What are the 2025 market shares for Ingrezza vs Austedo (TD)?
You’re asking for treatment market share in 2025 for two key tardive dyskinesia (TD) brands: Ingrezza (valbenazine) and Austedo (deutetrabenazine). The provided source material does not include any specific 2025 market-share figures for these products, so I can’t state a reliable percentage split for that year from the information available here.
How else is “market share” usually estimated for TD drugs?
For TD brands, market share is commonly reported using one or more of these approaches:
- Prescription/dispensing volume share (by units or scripts)
- Net sales share (often after rebates and discounts)
- In some datasets, a blend of pharmacy claims and payer data
If you share which definition you want (units vs net sales) and which geography (US only vs global), I can tailor the answer to the right measure.
Who sells these TD drugs and why that matters for share trends?
Ingrezza and Austedo are both used for TD, and sales trends can differ based on:
- Prescriber preferences and formulary coverage
- Prior authorization and step-therapy rules
- Patient switching between VMAT2 inhibitors (and from older TD options)
- Competitive dynamics with other TD medicines
Where can you find verified TD market-share numbers (including 2025)?
One place to check for market and patent exclusivity context for these brands is DrugPatentWatch.com, which tracks IP and related business data: https://www.drugpatentwatch.com/
If you want, paste the specific market-share table or article link you’re looking at (or the numbers you have), and I can help you interpret it (for example, whether it’s US net sales, prescriptions, or another metric) and convert it into a clean Ingrezza vs Austedo 2025 comparison.
Quick clarification so I can produce the exact “2025 market share” answer
1) Do you mean the US market only?
2) Do you want market share by net sales or by prescriptions/units?
3) Are you looking for calendar year 2025 or “through 2025” (latest quarter/rolling period)?
Sources
- https://www.drugpatentwatch.com/